3PC-005 Stability study of a 10% sodium benzoate oral solution

BackgroundDefects in the urea cycle are genetic diseases in which nitrogen accumulates as ammonia, resulting as highly toxic, especially in paediatric patients. Sodium benzoate (SB) is conjugated with glycine, giving rise to hippurate, which is excreted in the urine. Currently there are only intrave...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of hospital pharmacy. Science and practice 2019-03, Vol.26 (Suppl 1), p.A39-A39
Hauptverfasser: Castro Balado, A, Bayón Fernández, A, Adán Barrientos, I, Giráldez Montero, JM, Varela Rey, I, Fernández Ferreiro, A, González Barcia, M, Zarra Ferro, I
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page A39
container_issue Suppl 1
container_start_page A39
container_title European journal of hospital pharmacy. Science and practice
container_volume 26
creator Castro Balado, A
Bayón Fernández, A
Adán Barrientos, I
Giráldez Montero, JM
Varela Rey, I
Fernández Ferreiro, A
González Barcia, M
Zarra Ferro, I
description BackgroundDefects in the urea cycle are genetic diseases in which nitrogen accumulates as ammonia, resulting as highly toxic, especially in paediatric patients. Sodium benzoate (SB) is conjugated with glycine, giving rise to hippurate, which is excreted in the urine. Currently there are only intravenous SB commercial presentations, but no oral preparation is commercialised. Due to this, its manufacture in hospital pharmacy services is necessary.PurposeThe main objective is to evaluate the stability of an oral solution of 10% SB at different storage conditions for the treatment of urea cycle disorders in paediatric patients.Material and methodsInitially, six 10% SB samples were prepared from the commercial SB powder (Acofarma) and sterile water. Three were kept at room temperature and three were stored at 2°C–8°C during 30 days, protected from light. On the other hand, SB was characterised spectrophotometrically in water, to obtain a calibration curve. We studied several physical and chemical parameters after preparation (day 0) and after 7 and 30 days. These parameters were colour, opacity and the presence of precipitation, absorbance and pH. Each preparation was visually inspected in front of a black and white background. pH measurements were carried out by pH indicator strips. All absorbance measurements were obtained after dilution of solutions, with a Shimadzu spectrophotometer model UVmini-1240 UV-Vis.ResultsAll 10% SB solutions were initially homogenous and transparent. A calibration curve was obtained at 223 nm (y=56 495x+0.0177; R2=0.9995), with an average recovery percentage of 99.92% (SD=1.21; CV=1.21). On day 7 post-elaboration, an average degradation of 1.49% of active ingredient was observed in room-temperature stored samples and 2.82% in refrigerated samples. On day 30, the percentage of loss increased to 2.55% and 3.48% respectively. After 30 days, no colour change, no opacity and no precipitation were observed. In all test solutions the pH-values remained unchanged.ConclusionThe results allow us to conclude that our 10% SB oral solution, used in urea cycle defects in paediatric patients, are physically and chemically stable for at least 30 days when stored at room temperature or at 5°C±3°C with protection from light.References and/or acknowledgementsN/A.No conflict of interest.
doi_str_mv 10.1136/ejhpharm-2019-eahpconf.86
format Article
fullrecord <record><control><sourceid>proquest_bmj_p</sourceid><recordid>TN_cdi_proquest_journals_2190014271</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2190014271</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1246-13aa0c3c0b6ae3000b90a407f25b8ffeaf5b5762b6d33fcb22b8e4bc799c5b9b3</originalsourceid><addsrcrecordid>eNo9kMtKAzEYhYMoWGrfISIuo3-uM9kpxRsUFNR1yD9N6JSZyTiXRV258UV9EltqXZ3D4XAOfIScc7jiXJrrsF61K9_VTAC3LPhVW6QmXuXmiEwEqIxZa9Txv9fmlMz6vkTQUuZWSTshN_JlzgD0z9f36-CxrMphQ_thXG5oitRTDpe0T8tyrCmG5jP5IdDU-WobVuNQpuaMnERf9WH2p1Pyfn_3Nn9ki-eHp_ntgiEXyjAuvYdCFoDGBwkAaMEryKLQmMcYfNSoMyPQLKWMBQqBeVBYZNYWGi3KKbnY77Zd-hhDP7h1Grtme-kEtwBciYxvW2rfwnrt2q6sfbdxHNwOlzvgcjtc7oDL5Ub-AsaSYpY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2190014271</pqid></control><display><type>article</type><title>3PC-005 Stability study of a 10% sodium benzoate oral solution</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Castro Balado, A ; Bayón Fernández, A ; Adán Barrientos, I ; Giráldez Montero, JM ; Varela Rey, I ; Fernández Ferreiro, A ; González Barcia, M ; Zarra Ferro, I</creator><creatorcontrib>Castro Balado, A ; Bayón Fernández, A ; Adán Barrientos, I ; Giráldez Montero, JM ; Varela Rey, I ; Fernández Ferreiro, A ; González Barcia, M ; Zarra Ferro, I</creatorcontrib><description>BackgroundDefects in the urea cycle are genetic diseases in which nitrogen accumulates as ammonia, resulting as highly toxic, especially in paediatric patients. Sodium benzoate (SB) is conjugated with glycine, giving rise to hippurate, which is excreted in the urine. Currently there are only intravenous SB commercial presentations, but no oral preparation is commercialised. Due to this, its manufacture in hospital pharmacy services is necessary.PurposeThe main objective is to evaluate the stability of an oral solution of 10% SB at different storage conditions for the treatment of urea cycle disorders in paediatric patients.Material and methodsInitially, six 10% SB samples were prepared from the commercial SB powder (Acofarma) and sterile water. Three were kept at room temperature and three were stored at 2°C–8°C during 30 days, protected from light. On the other hand, SB was characterised spectrophotometrically in water, to obtain a calibration curve. We studied several physical and chemical parameters after preparation (day 0) and after 7 and 30 days. These parameters were colour, opacity and the presence of precipitation, absorbance and pH. Each preparation was visually inspected in front of a black and white background. pH measurements were carried out by pH indicator strips. All absorbance measurements were obtained after dilution of solutions, with a Shimadzu spectrophotometer model UVmini-1240 UV-Vis.ResultsAll 10% SB solutions were initially homogenous and transparent. A calibration curve was obtained at 223 nm (y=56 495x+0.0177; R2=0.9995), with an average recovery percentage of 99.92% (SD=1.21; CV=1.21). On day 7 post-elaboration, an average degradation of 1.49% of active ingredient was observed in room-temperature stored samples and 2.82% in refrigerated samples. On day 30, the percentage of loss increased to 2.55% and 3.48% respectively. After 30 days, no colour change, no opacity and no precipitation were observed. In all test solutions the pH-values remained unchanged.ConclusionThe results allow us to conclude that our 10% SB oral solution, used in urea cycle defects in paediatric patients, are physically and chemically stable for at least 30 days when stored at room temperature or at 5°C±3°C with protection from light.References and/or acknowledgementsN/A.No conflict of interest.</description><identifier>ISSN: 2047-9956</identifier><identifier>EISSN: 2047-9964</identifier><identifier>DOI: 10.1136/ejhpharm-2019-eahpconf.86</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><subject>Pediatrics</subject><ispartof>European journal of hospital pharmacy. Science and practice, 2019-03, Vol.26 (Suppl 1), p.A39-A39</ispartof><rights>2019, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>2019 2019, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Castro Balado, A</creatorcontrib><creatorcontrib>Bayón Fernández, A</creatorcontrib><creatorcontrib>Adán Barrientos, I</creatorcontrib><creatorcontrib>Giráldez Montero, JM</creatorcontrib><creatorcontrib>Varela Rey, I</creatorcontrib><creatorcontrib>Fernández Ferreiro, A</creatorcontrib><creatorcontrib>González Barcia, M</creatorcontrib><creatorcontrib>Zarra Ferro, I</creatorcontrib><title>3PC-005 Stability study of a 10% sodium benzoate oral solution</title><title>European journal of hospital pharmacy. Science and practice</title><description>BackgroundDefects in the urea cycle are genetic diseases in which nitrogen accumulates as ammonia, resulting as highly toxic, especially in paediatric patients. Sodium benzoate (SB) is conjugated with glycine, giving rise to hippurate, which is excreted in the urine. Currently there are only intravenous SB commercial presentations, but no oral preparation is commercialised. Due to this, its manufacture in hospital pharmacy services is necessary.PurposeThe main objective is to evaluate the stability of an oral solution of 10% SB at different storage conditions for the treatment of urea cycle disorders in paediatric patients.Material and methodsInitially, six 10% SB samples were prepared from the commercial SB powder (Acofarma) and sterile water. Three were kept at room temperature and three were stored at 2°C–8°C during 30 days, protected from light. On the other hand, SB was characterised spectrophotometrically in water, to obtain a calibration curve. We studied several physical and chemical parameters after preparation (day 0) and after 7 and 30 days. These parameters were colour, opacity and the presence of precipitation, absorbance and pH. Each preparation was visually inspected in front of a black and white background. pH measurements were carried out by pH indicator strips. All absorbance measurements were obtained after dilution of solutions, with a Shimadzu spectrophotometer model UVmini-1240 UV-Vis.ResultsAll 10% SB solutions were initially homogenous and transparent. A calibration curve was obtained at 223 nm (y=56 495x+0.0177; R2=0.9995), with an average recovery percentage of 99.92% (SD=1.21; CV=1.21). On day 7 post-elaboration, an average degradation of 1.49% of active ingredient was observed in room-temperature stored samples and 2.82% in refrigerated samples. On day 30, the percentage of loss increased to 2.55% and 3.48% respectively. After 30 days, no colour change, no opacity and no precipitation were observed. In all test solutions the pH-values remained unchanged.ConclusionThe results allow us to conclude that our 10% SB oral solution, used in urea cycle defects in paediatric patients, are physically and chemically stable for at least 30 days when stored at room temperature or at 5°C±3°C with protection from light.References and/or acknowledgementsN/A.No conflict of interest.</description><subject>Pediatrics</subject><issn>2047-9956</issn><issn>2047-9964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNo9kMtKAzEYhYMoWGrfISIuo3-uM9kpxRsUFNR1yD9N6JSZyTiXRV258UV9EltqXZ3D4XAOfIScc7jiXJrrsF61K9_VTAC3LPhVW6QmXuXmiEwEqIxZa9Txv9fmlMz6vkTQUuZWSTshN_JlzgD0z9f36-CxrMphQ_thXG5oitRTDpe0T8tyrCmG5jP5IdDU-WobVuNQpuaMnERf9WH2p1Pyfn_3Nn9ki-eHp_ntgiEXyjAuvYdCFoDGBwkAaMEryKLQmMcYfNSoMyPQLKWMBQqBeVBYZNYWGi3KKbnY77Zd-hhDP7h1Grtme-kEtwBciYxvW2rfwnrt2q6sfbdxHNwOlzvgcjtc7oDL5Ub-AsaSYpY</recordid><startdate>201903</startdate><enddate>201903</enddate><creator>Castro Balado, A</creator><creator>Bayón Fernández, A</creator><creator>Adán Barrientos, I</creator><creator>Giráldez Montero, JM</creator><creator>Varela Rey, I</creator><creator>Fernández Ferreiro, A</creator><creator>González Barcia, M</creator><creator>Zarra Ferro, I</creator><general>BMJ Publishing Group LTD</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>201903</creationdate><title>3PC-005 Stability study of a 10% sodium benzoate oral solution</title><author>Castro Balado, A ; Bayón Fernández, A ; Adán Barrientos, I ; Giráldez Montero, JM ; Varela Rey, I ; Fernández Ferreiro, A ; González Barcia, M ; Zarra Ferro, I</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1246-13aa0c3c0b6ae3000b90a407f25b8ffeaf5b5762b6d33fcb22b8e4bc799c5b9b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Pediatrics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Castro Balado, A</creatorcontrib><creatorcontrib>Bayón Fernández, A</creatorcontrib><creatorcontrib>Adán Barrientos, I</creatorcontrib><creatorcontrib>Giráldez Montero, JM</creatorcontrib><creatorcontrib>Varela Rey, I</creatorcontrib><creatorcontrib>Fernández Ferreiro, A</creatorcontrib><creatorcontrib>González Barcia, M</creatorcontrib><creatorcontrib>Zarra Ferro, I</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>European journal of hospital pharmacy. Science and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Castro Balado, A</au><au>Bayón Fernández, A</au><au>Adán Barrientos, I</au><au>Giráldez Montero, JM</au><au>Varela Rey, I</au><au>Fernández Ferreiro, A</au><au>González Barcia, M</au><au>Zarra Ferro, I</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>3PC-005 Stability study of a 10% sodium benzoate oral solution</atitle><jtitle>European journal of hospital pharmacy. Science and practice</jtitle><date>2019-03</date><risdate>2019</risdate><volume>26</volume><issue>Suppl 1</issue><spage>A39</spage><epage>A39</epage><pages>A39-A39</pages><issn>2047-9956</issn><eissn>2047-9964</eissn><abstract>BackgroundDefects in the urea cycle are genetic diseases in which nitrogen accumulates as ammonia, resulting as highly toxic, especially in paediatric patients. Sodium benzoate (SB) is conjugated with glycine, giving rise to hippurate, which is excreted in the urine. Currently there are only intravenous SB commercial presentations, but no oral preparation is commercialised. Due to this, its manufacture in hospital pharmacy services is necessary.PurposeThe main objective is to evaluate the stability of an oral solution of 10% SB at different storage conditions for the treatment of urea cycle disorders in paediatric patients.Material and methodsInitially, six 10% SB samples were prepared from the commercial SB powder (Acofarma) and sterile water. Three were kept at room temperature and three were stored at 2°C–8°C during 30 days, protected from light. On the other hand, SB was characterised spectrophotometrically in water, to obtain a calibration curve. We studied several physical and chemical parameters after preparation (day 0) and after 7 and 30 days. These parameters were colour, opacity and the presence of precipitation, absorbance and pH. Each preparation was visually inspected in front of a black and white background. pH measurements were carried out by pH indicator strips. All absorbance measurements were obtained after dilution of solutions, with a Shimadzu spectrophotometer model UVmini-1240 UV-Vis.ResultsAll 10% SB solutions were initially homogenous and transparent. A calibration curve was obtained at 223 nm (y=56 495x+0.0177; R2=0.9995), with an average recovery percentage of 99.92% (SD=1.21; CV=1.21). On day 7 post-elaboration, an average degradation of 1.49% of active ingredient was observed in room-temperature stored samples and 2.82% in refrigerated samples. On day 30, the percentage of loss increased to 2.55% and 3.48% respectively. After 30 days, no colour change, no opacity and no precipitation were observed. In all test solutions the pH-values remained unchanged.ConclusionThe results allow us to conclude that our 10% SB oral solution, used in urea cycle defects in paediatric patients, are physically and chemically stable for at least 30 days when stored at room temperature or at 5°C±3°C with protection from light.References and/or acknowledgementsN/A.No conflict of interest.</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/ejhpharm-2019-eahpconf.86</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2047-9956
ispartof European journal of hospital pharmacy. Science and practice, 2019-03, Vol.26 (Suppl 1), p.A39-A39
issn 2047-9956
2047-9964
language eng
recordid cdi_proquest_journals_2190014271
source EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Pediatrics
title 3PC-005 Stability study of a 10% sodium benzoate oral solution
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T21%3A33%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_bmj_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=3PC-005%E2%80%85Stability%20study%20of%20a%2010%25%20sodium%20benzoate%20oral%20solution&rft.jtitle=European%20journal%20of%20hospital%20pharmacy.%20Science%20and%20practice&rft.au=Castro%20Balado,%20A&rft.date=2019-03&rft.volume=26&rft.issue=Suppl%201&rft.spage=A39&rft.epage=A39&rft.pages=A39-A39&rft.issn=2047-9956&rft.eissn=2047-9964&rft_id=info:doi/10.1136/ejhpharm-2019-eahpconf.86&rft_dat=%3Cproquest_bmj_p%3E2190014271%3C/proquest_bmj_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2190014271&rft_id=info:pmid/&rfr_iscdi=true